Review: Pharmacotherapy as part of a weight management programme: a UK perspective

Abstract

Rates of obesity and overweight continue to rise and substantially increase the risk of morbidity and mortality from type 2 diabetes, coronary and mortality from type 2 diabetes, coronary heart disease and stroke. On the other hand, a sustained weight loss of 5—10% in the obese confers marked health benefits. Current strategies for the management of obesity include lifestyle interventions and pharmacotherapy. At present, three drugs are approved for the medical management of obesity in the UK: orlistat, sibutramine and rimonabant. All three agents are efficacious in reducing body weight but by different mechanisms. Although weight loss is an important treatment outcome, a major goal of obesity management should be to improve cardiovascular and metabolic risk factors in order to reduce obesity-related morbidity and mortality. Given the similar levels of weight loss achievable with currently approved agents, treatment decisions should include careful assessment of the effects of these agents on cardiovascular and metabolic risk factors and on their long-term safety profiles. Br J Diabetes Vasc Dis 2007;7:268-77

Keywords

lifestyle interventions obesity orlistat rimonabant sibutramine weight management.

Get full access to this article

View all access options for this article.

References

National Audit Office. Tackling Obesity in England. Report by the Comptroller and Auditor General . Norwich: The Stationery Office , 2001.

Government Statistical Service. Statistics on obesity, physical activity and diet: England, 2006. Available from: http://www.ic.nhs.uk/pubs/obesity/opan/file . Last accessed January 2007.

Van Gaal LF , Wauters MA , De Leeuw IH The beneficial effects of modest weight loss on cardiovascular risk factors . Int J Obes Relat Metab Disord 1997 ;21(suppl 1):S5-S9.

Jung R. Obesity as a disease. Br Med Bull 1997;53:307-21.

Williamson DF , Thompson TJ , Thun M. , Flanders D. , Pamuk E. , Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.

Knowler WC , Barrett-Connor E. , Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Engl J Med 2002 ;346:393-403.

Tuomilehto J. , Lindstrom J. , Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.with impaired glucosetolerance. N Engl J Med 2001;344:1343-50.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

MacMahon S. , Cutler J. , Brittain E. , Higgins M. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987;8(suppl B):57-70.

10.

Dattilo AM , Kris-Etherton PM Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis . Am J Clin Nutr 1992; 56:320-8.

11.

Linna MS , Borg P. , Kukkonen-Harjula K. et al. Successful weight maintenance preserves lower levels of oxidized LDL achieved by weight reduction in obese men. Int J Obes (Lond) 2006 Jun 27; [Epub ahead of print].

12.

Central Office of Information for the Department of Health. Care pathway for the management of overweight and obesity, May 2006. Available from: http://www.dh.gov.uk/assetRoot/04/13/45/60/04134560.pdf . Last accessed January 2007.

13.

National Institute for Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children (Guideline CG43) . London: NICE 2006 (www.nice.org.uk).

14.

Astrup A. , Grunwald GK , Melanson EL , Saris WH , Hill JO The role of low fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 2000;24:1545-52.

15.

Bray G. , Popkin BM

Dietary fat intake does affect obesity!

Am J Clin Nutr 1998;68:1157-73.

16.

Lindstrom J. , Peltonen M. , Eriksson JG et al. High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia 2006;49:912-20.

17.

Curioni CC , Lourenco PM Long-term weight loss after diet and exercise: a systematic review . Int J Obes (Lond) 2005;29:1168-74.

18.

The Chief Medical Officer's report, At Least Five A Week: Evidence on the Impact of Physical Activity and its Relationship to Health, April 2004. Available from: http://www.dh.gov.uk/assetRoot/04/08/09/83/04080983.pdf. Last accessed January 2007.

19.

Klein S. , Wadden T. , Sugerman HJ AGA technical review on obesity. Gastroenterology 2002;123:882-932.

20.

Stevens VJ , Obarzanek E. , Cook NR et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001;134:1-11.

21.

Roche Prescribing Information 2005. Available from: http://www.rocheusa.com/products/xenical/pi.pdf. Accessed January 2007.

22.

Zhi J. , Melia AT , Guerciolini R. et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of Orlistat in normal and obese volunteers . Clin Pharmacol Ther 1994;56:82-5.

23.

Avenell A. , Brown TJ , McGee MA et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004;17:293-316.

24.

Torgerson JS , Hauptman J. , Boldrin MN , Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients . Diabetes Care 2004;27:155-61.

25.

Padwal R. , Li SK , Lau DCW. Long-term pharmacotherapy for overweight and obesity. Int J Obes Relat Metab Disord 2003;27:1437-46.

26.

Richelsen B. , Tonstad S. , Rossner S. et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients. A 3-year randomized, placebo-controlled study. Diabetes Care 2007;30:27-32.

27.

Roche UK Orlistat Summary of Product Characteristics. Available from: http://www.rocheuk.com/ProductDB/Documents/rx/spc/Xenical_SPC.pdf Last accessed January 2007.

28.

Nisoli E. , Carruba MO An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000;1:127-39.

29.

Hansen DL , Toubro S. , Stock MJ , Macdonald IA , Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016-24.

30.

Apfelbaum M. , Vague P. , Ziegler O. , Hanotin C. , Thomas F. , Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.

31.

James WP , Astrup A. , Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356:2119-25.

32.

Van Gaal LF , Wauters MA , Peiffer FW , De Leeuw IH Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral

33.

fat reduction?

Int J Obes Relat Metab Disord 1998;22(suppl 1):S38-S40. 33. McMahon FG , Weinstein SP , Rowe E. , Ernst KR , Johnson F. , Fujioka K. ; Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors . J Hum Hypertens 2002;16:5-11.

34.

Hazenberg BP Randomized, double-blind, placebo-controlled, multi-center study of sibutramine in obese hypertensive patients. Cardiology 2000;94:152-8.

35.

Fanghanel G. , Cortinas L. , Sanchez-Reyes L. , Gomez-Santos R. , Campos-Franco E. , Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther 2003;20:101-13.

36.

Gursoy A. , Erdogan MF , Cin MO , Cesur M. , Baskal N. Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension. Endocr Pract 2005;11:308-12.

37.

European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products opinion following an article 31 referral: sibutramine. 2002: http://www.emea.eu.int/pdfs/human/referral/451402en.pdf. Last accessed January 2007.

38.

James WPT . The SCOUT study risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005;7(suppl L):L44-L48.

39.

Arterburn DE , Crane PK , Veenstra DL The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.

40.

Meridia product monograph. Mount Olive, NJ: Knoll Pharmaceutical; November 1998.

41.

Després JP , Golay A. , Sjostrom L. for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 ;353:2121-34.

42.

van Gaal LF , Rissanen AM , Scheen AJ , Ziegler O. , Rossner S. , for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.

43.

Pi-Sunyer FX , Aronne LJ , Heshmati HM , Devin J. , Rosenstock J. , for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006 ;295:761-75.

44.

Scheen AJ , Finer N. , Hollander P. , Jensen MD , Van Gaal LF ; RIO Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 2006;368:1160-72.

45.

Curioni C. , Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006;18:CD006162.

46.

Acomplia Summary of Product Characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/acomplia-updated_pi_july07.pdf . Last accessed September 2007.

47.

Acharya NV , Wilton LV , Shakir SA Safety profile of orlistat: results of a prescription-event monitoring study . Int J Obes (Lond) 2006;30:1645-52.

48.

The safety of orlistat and sibutramine: a summary of the prescription-event monitoring data. Obes Res 2005;13(suppl):A1-A218.

49.

Allison DB , Fontaine KR , Heshka S. , Mentore JL , Heymsfield SB Alternative treatments for weight loss: a critical review. Crit Revs Food Sci 2001;41:1-28.

50.

Pittler MH , Ernst E. Dietary supplements for body-weight reduction: a systematic review . Am J Clin Nutr 2004;79:529-36.

51.

Connolly HM , Crary JL , McGoon MD Det al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.

52.

Hutchins GM Dietary supplements containing ephedra alkaloids . N D Engl J Med 2001;344:1095-6.

53.

Eliason BC , Doenier, JA , Nuhlicek DN Desiccated thyroid in a nutritional supplement. J Fam Pract 1994;38:287-8.

54.

Adachi M. , Saito H. , Kobayashi H. et al. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido. Ann Intern Med 2003 ;139:488-92.

55.

Dunican KC , Desilets AR , DeBellis RJ State of the art review: long-term pharmacotherapy for overweight and obesity: a review of sibutramine, orlistat, and rimonabant. Am J Lifestyle Med 2007;1:367-88.

56.

Sjöström L. , Rissanen A. , Andersen T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of regain in obese patients . Lancet 1998;352:167-72.

57.

Hill, JO , Hauptman J. , Anderson JW et al. Orlistat, a lipase inhibitor for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69:1108-16.

58.

Davidson MH , Hauptman J. , DiGirolamo M. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42.

59.

Finer N. , James WPT , Kopelman PB , Lean MEJ , Williams G. One-year treatment of obesity: a randomized double blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes 2000;24:306-13.

60.

Rössner S. , Sjöström L. , Noack R. , Meinders AE , Noseda G. Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61.

61.

Hauptman J. , Lucas C. , Boldrin MN , Collins H. , for the Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-7.

62.

Krempf M. , Louvet JP , Allanic H. , Miloradovich T. , Joubert J-M. , Attali J. -R. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes 2003 ;27:591-7.

63.

Smith IG , Goulder MA Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001 ;50:505-12.

64.

Wadden TA , Berkowitz RI , Sarwer DB , Prus-Wisniewski R. , Steinberg C. Benefits of lifestyle modifications in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001;161:218-27.

65.

Porter JA , Raebel MA , Conner DA et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organisation. Am J Manag Care 2004;10:369-76.

66.

Wadden TA , Berkowitz RI , Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20.

67.

Cuellar GEM , Ruiz AM , Monsalve MCR , Berber A. Six month treatment of obesity with sibutramine 15mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000;8:71-82. 68. Fanghänel G. , Cortinas L. , Sanchez-Reyes L. , Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 2000;24:144-50.

68.

Wirth A. , Krause J. Long-term weight loss with sibutramine. JAMA 2001;286:1331-9.

69.

Mathus-Vliegen EMH . Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr 2005;59:S31-S39.

70.

Hauner H. , Meier M. , Wendland G. , Kurscheid T. , Lauterbach K. Weight reduction by sibutramine in obese subjects in primary care medicine: The S.A.T study. Exp Clin Endocrinol Diabetes 2004;112:201-07.